Staar Surgical raises 2024 sales outlook to $340M-$345M from $335M-$340M

Consensus $339.97M. Sees adjusted EBITDA per diluted share of approximately 80c, increased from the prior outlook of 75c. The company said, “STAAR is truly disrupting the refractive industry to benefit our surgeon customers, their patients and our shareholders. We are moving down the diopter curve and as a result are beginning to realize our near-term goal of becoming the choice for surgeons and their patients -6D of myopia and above. Given our momentum and the opportunity before us, we are raising our outlook for net sales, now to be in the range of $340 million to $345 million and Adjusted EBITDA to be approximately $42 million for fiscal 2024.”